

Egetis Therapeutics - All eyes on eventful 2024

Redeye updates its view of Egetis following the Q3 report and recent events in the company. We still see significant upside in Egetis and argue that the company has made important progress recently, most importantly EMA submission and a strong financing solution, that should lead to an eventful and transformative 2024 if timelines are kept.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Egetis Therapeutics - All eyes on eventful 2024](#)